

Emergence of *Raoultella ornithinolytica* producing beta lactamase enzyme in different clinical specimens in Erbil city

Abstract

Background: *Raoultella ornithinolytica* should never be regarded as merely a saprophytic bacterium that occasionally contaminates bronchial lavage or other deep respiratory samples or surgical sites. It is an underreported, emerging hospital-acquired infection and is particularly related with invasive operations. *R. ornithinolytica* isolates have significant antimicrobial resistance rates, and physicians should be aware of this so that, before accurate microbiological data are received, an immediate broad-spectrum antibiotic treatment can be instituted.

Objectives: The goal of our study was to retrospectively examine *R. ornithinolytica*, which was isolated from a variety of clinical samples in Erbil, and to examine its epidemiology, antibiotic sensitivity patterns, and ability to produce the enzyme extend spectrum beta lactamase.

Methods: A total of 2350 samples were collected from three different sources (Urine, High vaginal swab and wound), collected from female and male from patient attending Rizgary hospital and Central lab in Erbil city during the July 2017 to February 2018. Only 10 cases had been identified as *R. ornithinolytica* and all isolates isolated and identified by using microscopical, morphological, biochemical tests and Vitek 2 compact system. Also antibiotics susceptibility testing was performed by using Vitek 2 compact system according to the standard protocol against 13 antibiotics which are (Ampicillin / Sulbactam, Piperacillin / Tazobactam, Cefazolin, Ceftazidim, Ceftriaxon, Cefepime, Levofloxacin, Trimethoprim / Sulfamethoxazol, Gentamycin, Tobramycin, Ertapenem, Imipenem, Ciprofloxacin).

Results: Only ten *R. ornithinolytica* isolates isolated from 2350 distribution according to their source of isolation High vaginal swab 6(0.23%) appeared to be the most dominant specimen than other specimens followed by urine sample 3(0.13%) then wound 1(0.04%). The highest percentage of *R. ornithinolytica* isolated from female. Most isolates from high vaginal swab sample 6(0.26%) followed by urine 3 (0.13%) then wound 1(0.04%), when performing of antibiotic susceptibility the highest resistances rate were to Cefazolin and Trimethoprim / Sulfamethoxazol 10 (100%) followed by Ampicillin / Sulbactam, Piperacillin / Tazobactam, Ceftriaxon, Gentamycin, Tobramycin and Ciprofloxacin 7(70%) for each, 6(60%) isolates ESBL producer, all isolated *R. ornithinolytica* were resistance to more than 8 antibiotics and two isolates completely resistance to all thirteen antibiotics.

Conclusion: The overall prevalence of *R. ornithinolytica* isolates was low in Erbil city and we can be observed and isolated from various clinical samples and causes serious infections and susceptibility to some antibiotics are low and also most isolates multiresistance and ESBL producers and These findings offer a reliable measure of the prevalence of *Raoultella ornithinolytica* in our region and provide a baseline for future studies that will enable the

monitoring of trends over time. If current resistance trends continue, high societal and economic costs can be anticipated; better management of infections caused by resistance *R. ornithinolytica* is becoming essential.

Keyword: *Raoultella ornithinolytica*, antibiotics resistances , ESBL.

Introduction

“*Raoultella ornithinolytica* is Gram-negative, encapsulated, oxidase-negative, catalase-positive, nonmotile, facultatively anaerobic rods formerly known as *Klebsiella* make up the Enterobacteriaceae family. It is named after the French bacteriologist Didier Raoult”. (1). “*Raoultella* spp. based on their molecular features, have recently been split from the genus *Klebsiella*” (2). “This genus was discovered in samples of human tissue as well as water, soil, plants, and occasionally animal mucosa. Type species is *Raoultella ornithinolytica* comb. nov. *Raoultella planticola* comb. nov. and *Raoultella terrigena* comb. Nov (3) *R. ornithinolytica* resides in hospitals and is known to inhabit aquatic habitats” (4). The results of the 16S rRNA sequence studies, in addition to previously published biochemical and DNA-DNA hybridization data, demonstrated that the genus *Klebsiella* is heterogeneous and made up of species that form three clusters that also contain members of other genera. These findings are in favor of splitting the genus *Klebsiella* into two genera. For species in cluster II, the genus name *Raoultella* is suggested which contained *Klebsiella ornithinolytica*, *Klebsiella planticola*, and *Klebsiella terrigena*, organisms characterized by growth at 10°C and utilization of L-sorbose as carbon source ⁽¹⁾. On the basis of new genetic techniques, the bacterium, formerly identified as *Klebsiella ornithinolytica*, was reclassified as *Raoultella* (1). Sakazaki et al. provided the first description of this bacterium in 1989 (5). *Raoultella* species have never been isolated from clinical specimens and are believed to only exist in aquatic, botanical, and soil habitats (6). Monnet et al. reported the first isolation of *R. planticola* from neonates in neonatal wards (7). “There have been few reports of *R. ornithinolytica*, an aquatic gram-negative commensal of the Enterobacteriaceae family, surviving in human saliva. *R. ornithinolytica* has developed into a human pathogen in a number of illnesses that are contracted in the community or hospitals” (8). “The analysis of 16S rDNA and rpoB sequences produced data that support the varied taxonomic structure of the genus *Klebsiella*. The same reports that this bacteria has been linked to human diseases such as peritonitis and enteric fever-like syndrome have surfaced. This species has been linked to histamine seafood poisoning” (9). These environmental organisms appear to have pathogenicity similar to *Klebsiella pneumoniae* (10), although seldom infecting humans. Bloodstream infections have sporadically been reported; the first invasive *Raoultella* spp.

infection in a human was originally recorded in 1984. Ten cases of *R. ornithinolytica* infection have been recorded, connecting this pathogen to bacteremia, sepsis, soft tissue infections, and other illnesses over the past ten years. *R. ornithinolytica* is an important but antifungal cause of human infection.⁽¹²⁾ . “Hospital acquired urinary tract infections are frequently brought on by the ability of bacteria to colonize the inner surfaces of indwelling urinary catheters. Hence, it is believed that these pathways may be crucial in the pathogenesis of infection. Understanding the connection between *R. ornithinolytica* human infections and invasive operations like the insertion of venous catheters, intra-vascular prosthesis, or orthopedic devices would be made easier with the help of other virulence factors, such the capacity to build biofilms”.⁽¹³⁾ . “The percentage of *R. ornithinolytica* isolates with decreased antibiotic susceptibility was comparatively high. The mechanism of beta-lactam resistance exhibited by *R. ornithinolytica* isolates depends on a chromosomal bla gene”⁽¹⁴⁾ . “AmpC -lactamases are-lactamases that hydrolyze penicillins, cephalosporins, and cephamycins (cefoxitin), and are not inhibited by clavulanic acid. (β -lactamase inhibitor- β -lactam combinations)”⁽¹⁵⁾.

METHODS

Samples collection

From six distinct sources, a total of(2350) samples were obtained (urine, wound swab, high vaginal swab, feces, throat swab,csf). Each bacterial isolate was put through a battery of confirmation assays after being collected. The findings revealed that only ten isolates were identified as *R. ornithinolytica*. Patients who visited the Central Lab and Rizgari Hospital in Erbil City throughout the time period had their clinical samples taken (July 2017 to February 2018) from patients between the ages of 10 and79, both male and female. Blood culture and MacConkey agar plates were cultured aerobically at 37°C for (24–48 hours) in order to isolate bacteria from the samples. Blood culture and MacConkey agar plates were cultured aerobically at 37°C for (24–48 hours) in order to isolate bacteria from the samples. Using morphological and biochemical testing, pure colonies of isolated microorganisms ,Vitek 2 technology was used to identify species and generate antibiograms for infections⁽¹⁶⁾.

Antimicrobial susceptibility test by Vitek 2 system

The Vitek 2 system was used to test all isolates for their resistance to 13 different antibiotics. Because it can accurately identify the "fingerprint" of bacterial resistance

mechanisms and phenotypes, the AES is a key part of the Vitek 2 system. 64 micro wells are present on the Vitek 2 card. Antimicrobials or identifying substrates are present in each well. For the identification of organisms and assessing their susceptibility to antibiotics, Vitek 2 provides a complete menu. Because the Vitek 2 test card is sealed, the likelihood of spills, aerosols, and individual contamination is reduced. Compared to microtiter technologies, disposable waste is decreased by more than 80% (16).

Phenotypic screening for ESBL

Each isolate was tested using the VITEK 2 system with the antimicrobial susceptibility test extend AST-EXN8 card. This system was designed to perform both screening and confirmatory tests for phenotypic detection of ESBL on the same plate. The test comprises a panel of six wells containing ceftazidime 0.5 mg/L, cefotaxime 0.5 mg/L and cefepime 1.0 mg/L, the rest of three wells were filled with same three antibiotics in combination with clavulanic acid (4, 4 and 10 mg/L, respectively). An optical reader was used to objectively measure growth in each well. When compared to wells containing cephalosporin alone, the proportional decrease in growth in the wells having cephalosporin + clavulanate was thought to be an indication of ESBL development. The results of all phenotypic ESBL interpretations were reported as positive. When the AES suggested phenotypic interpretations other than ESBLs, strains were described as ESBL-negative (16).

Results

Distribution of *R.ornithinolytica* according to location of Erbil city

Prevalence of *R.ornithinolytica* was highest in Central Lab (0.25%) ,While the lowest prevalence of *R.ornithinolytica* found in Rizgari Lab (0.27%) as show in table (1).

Table (1): Distribution of *R.ornithinolytica* according to location of Erbil city

Hospitals	NO.of (+ve)samples	NO.of(-ve)samples	Total
Rzgari lab	4	1428	1432
	0.17%	60.70%	60.93%

Central lab	6	912	918
	0.25%	38.81%	39.06%
Total	10	2340	2350
	0.42%	99.57%	100%

Relation between *R.ornithinolytica* and gender (female , male)

Out of 2350 samples ,10 samples were isolated for *R.ornithinolytica*, the highest percentage of *R.ornithinolytica* in female 9 (0.38%) was higher than those in male patients 1 (0.043% as show in table (2).

Table (2): Relation between *R.ornithinolytica* and gender(female,male)

Patient	(+ve) samples	(-ve)samples	Total
Male	1	1069	1070
	0.043%	46.63%	45.53%
Female	9	1271	1280
	0.38%	54.09%	54.47%
Total	10	2340	2350
	0.43%	99.57%	100%

The incidence of *R.ornithinolytica* in different clinical specimens.

Out of 2350 samples 10 sample isolates distribution according to their source of isolation More than half of these infections were contributed by female genital tract 6(0.26%)and in the second position comes UTI, 3(0.13%)while only one (0.04%)wound infections has been detected . as in table (3) and in figure(1).

Table(3)The incidence of *R.ornithinolytica* in different clinical specimens

Patient	Number and percentage of <i>R.ornithinolytica</i>

	Urine	High vaginal swab	Wound	Total
Infected	3	6	1	10
	0.13%	0.26%	0.04%	0.43%
Uninfected	781	930	629	2340
	33.23%	39.57%	26.76%	99.56%
Total	784	936	630	2350

Antibiotics	NO.Sensitive	Percentage %	NO.Resistant	Percentage %
	33.36%	39.82%	26.80%	100%




Figure (1):The incidence of *R.ornithinolytica* in different clinical specimens.

The number and percentage of antibiotic resistance among *R.ornithinolytica*

All *R.ornithinolytica* isolated were tested for antimicrobial susceptibility testing, *R.ornithinolytica* isolates showed highest sensitive (90%) to cefepime & imipenem, Ertapenem and Ceftazidium and levofloxacin, as shown in table (4) and in figure (2), on the other hand isolates were ESBL producers and multi resistance.

Table (4) The number and percentage of antibiotic resistance among *R.ornithinolytica*

Ampicillin/Sulbactam	3	30%	7	70%
Piperacillin/Tazobactam	3	30%	7	70%
Cefazolin	0	0%	10	100%
Ceftazidim	9	90%	1	10%
Ceftriaxon	3	30%	7	70%
Cefepime	9	90%	1	10%
Levofloxacin	9	90%	1	10%
Trimethoprim/Sulfamethoxazol	0	0%	10	100%
Gentamycin	3	30%	7	70%
Tobramycin	3	30%	7	70%
Ertapenem	9	90%	1	10%
Imipenem	9	90%	1	10%
Ciprofloxacin	3	30%	7	70%




Figure (2) The number and percentage of antibiotic resistance among *R.ornithinolytica*

Antibiotic susceptibility patterns for ESBL producer *R.ornithinolytica* isolates

The bacterial isolates revealed remarkable variation in their resistance and sensitive antibiotics used, but in general most isolates of *R.ornithinolytica* were multi drug resistance to more than seven antibiotics and six of them ESBL producers as in table (5).

Table (5): Antibiotic susceptibility patterns for ESBL producer *R.ornithinolytica* isolates

Antibiotics	R1	R2	R4	R5	R7	R10	NO.S	NO. R
Ampicillin/Sulbactam	R	R	R	R	R	R	0	6
Piperacillin/Tazobactam	R	R	R	R	R	R	0	6
Cefazolin	R	R	R	R	R	R	0	6
Ceftazidim	S	R	S	S	S	S	5	1
Ceftriaxone	R	R	R	R	R	R	0	6
Cefepime	S	R	S	S	S	S	5	1
Levofloxacin	S	R	S	S	S	S	5	1
Trimethoprim/Sulfamethoxazole	R	R	R	R	R	R	0	6
Gentamicin	R	R	R	R	R	R	0	6
Tobramycin	R	R	R	R	R	R	0	6
Ertapenem	S	R	S	S	S	S	5	1
Imipenem	S	R	S	S	S	S	5	1
Ciprofloxacin	R	R	R	R	R	R	0	6

DISCUSSION AND CONCLUSION

Frequency of isolated *Raoultella ornithinolytica*

The greatest recorded case of *R. ornithinolytica* infection in humans occurred during a 12-year period at four university hospital centers in France. The greatest recorded case of *R. ornithinolytica* infection in humans occurred during a 12-year period at four university hospital centers in France. 86 instances of *R. ornithinolytica* (formerly *Klebsiella ornithinolytica*) were found in the literature(17), with half of these cases being published in 2015. (18). Out of 2350 samples that were tested in 2017 in Erbil city by Rizgary and Central laboratories, 10(3.93%) (positive for *R. ornithinolytica*, 4(0.71%)) isolates were obtained from Rizgary Hospital, while 6(0.25) isolates were obtained from Central laboratory. In other words, the Vitek 2 compact system, along with microscopical, morphological, and biochemical analyses, allowed us to identify *R. ornithinolytica* in(0.43%) of the samples we collected in 2017., our study yielded lower findings than those noted by Hansen from Thi-Qar (19). Twenty *Raoultella* spp. isolates were detected in Iraq from 229 positive specimens, whereas *R. ornithinolytica* reported 16 isolates, or 6.98% of the total *Raoultella* recovered from clinical specimens (20). Additionally discovered that the majority of isolates (8(72.7%)) of the 11 *R. ornithinolytica* were isolated from 174 rectal swab and stool samples and Kuhn et al.(21) who discovered that the primary reservoirs of *Klebsiella* transmission in hospitals are the gastrointestinal tract of patients and hands of hospital personnel and outcomes). reported by Podschun *et al* ⁽¹³⁾ There are only three case reports of human infection by *R. ornithinolytica*; the first patient was an 82-year-old woman in whom the microorganism caused an enteric fever-like syndrome; the organism was isolated from blood. Research has shown that a high rate(68%) of *Klebsiella* was isolated from faces (16) The second patient was a 97-year-old woman who had a huge renal cyst that was obstructing her colic. The cyst's fluid culture was positive for *R. ornithinolytica* (22). An child with visceral heterotaxy and *R. ornithinolytica* bacteremia was the third case to be documented. Just this particular example displayed noticeable skin flushing, which may have been caused by a histamine reaction(23). Research has demonstrated that the incidence of these organisms in clinical settings might vary geographically and that between 0.2% and 19.0% of isolates initially identified by 16S rRNA analysis as *Klebsiella* spp. were *Raoultella* spp (10) . Studies and research on infections caused by *R. ornithinolytica* in humans are urgently needed. Sadly, given how challenging it is to distinguish the bacterium using phenotypic techniques, this is an underappreciated problem. Health risks associated with this bacteria should not be disregarded. To distinguish the *Raoultella* species, a variety of phenotypic biochemical identification tests were available. A number of biochemical reactions were used to identify *R. ornithinolytica*, and the primary positive reactions were seen for urea, ornithine and lysine decarboxylase, citrate, glucose, and sucrose. It typically grows at a temperature of 10 °C with L-sorbose being used as a carbon source(19). All of the bacterial isolates were identified by a battery of laboratory tests to ensure that the results were accurate and that the isolates belonged to *R. ornithinolytica*. A number of biochemical reactions were used to identify *R. ornithinolytica*, and the primary positive reactions were seen for urea, ornithine and lysine decarboxylase, citrate, glucose, and sucrose. It typically grows at a temperature of 10 °C with L-sorbose being used as a carbon source(19). All of the bacterial isolates were identified by a battery of laboratory tests to ensure

that the results were accurate and that the isolates belonged to *R. ornithinolytica*. Gram negative bacteria that are red to pink in color, rod-shaped, occurring singly, in pairs, in short chains, and irregularly spaced apart make up this bacterial cell from the smear preparation. *R. ornithinolytica* tested positive for catalase as well, it turned out. Other biochemical tests were conducted, such as H₂S and Voges-Proskauer, which were negative for Raoultella, and the organism appeared to be oxidase negative, which means that the bacteria is not producing cytochrome c oxidase enzyme (colorless color). The immediate formation of oxygen bubbles is evidence that the organism is catalase positive. can be recognized on a Gram stain as a rare human pathogen that is a Gram-negative anaerobic bacillus closely related to Klebsiella. However, due to its rarity, it may be challenging to identify. Although Raoultella can resemble Klebsiella in appearance, Alves et al.(24) stated that Raoultella will typically be oxidase-and Voges-Proskauer-negative and that culture and biochemical assays will typically indicate fermentation of lactose and acid generation on MacConkey agar. Additionally, Raoultella should not produce H₂S and will typically not show arginine or phenylalanine Raoultella fermented glucose, used citrate, lysine, malonate, and l-sorbose, were urease-and methyl red-positive, were nonmotile, positive for indole production, histamine assimilation, and growth at 10°C. Additionally, Raoultella shouldn't produce H₂S and typically won't show arginine or phenylalanine utilization. There are three phyletic lines in the genus Klebsiella that it shared with other Enterobacteriaceae species, such as Enterobacter aerogenes, Erwinia and Tatumella. Cluster I comprises *K.pneumoniae* subspecies *pneumoniae*, *rhinoscleromatis* and *ozaenae*, and *K. granulomatis*; cluster II contains *R.ornithinolytica*, *R. planticola*,and *R.terrigena*; and cluster III contains *K. oxytoca*, sproser et al(25) ,kwon et al⁽²⁶⁾ *R. ornithinolytica* cases can be hard to distinguish from *K. oxytoca* in clinical labs using common phenotypic identification tools like the API 20E test kit and Vitek 2 GN ID card. Only one biochemical test—the ornithine decarboxylase (ODC) test—was available in the API 20E system to distinguish between *R. ornithinolytica* and *K. oxytoca*. The Vitek 2 system had five biochemical tests that might distinguish ODC-negative *R. ornithinolytica* isolates, however due to the lack of specificity, this method had to be verified by molecular identification (16S rRNA gene sequencing).The incidence of *R. ornithinolytica* in different specimens

“ *R. ornithinolytica* is an underreported, emerging hospital-acquired infection and is particularly associated with invasive procedures, should never be considered simply a saprophytic bacterium that occasionally contaminates bronchial lavage or other deep respiratory samples or surgical sites. Physicians should be aware of the high rates of antimicrobial resistance of *R. ornithinolytica* isolates so that immediate broad-spectrum antibiotic treatment can be established before accurate microbiological results are obtained” (27).In presence study out of 2350 samples only 10 (0.43%) case of infection with *R.ornithinolytica* were detected. More than half of these infections were contributed by female genital tract and in the second position comes UTI,while only one wound infections has been detected .The result agree with the finding obtained by Seleden et al (28) who found that that only 3 (27.3%) isolates of *R. ornithinolytica* were detected in 503 urine samples, but disagree with this result about no isolates were detected in vagina, ear, and wound samples, Kuhn et al⁽²¹⁾ recorded that the principle reservoirs of transmission of this bacteria in hospital setting are the gastrointestinal tract of patient and hand of hospital personal. “Till now the cases reported of *R.ornithinolytica* has a very low

mortality rate and a good prognosis unlike other gram negative bacteria .Although *R. ornithinolytica* a rare hospital infection, it should be kept in mind as a cause, by virtue of the fact that it is a part of the flora in natural environment. The pathogenic potential of *R.ornithinolytica* isolates in human disease has become increasingly important. Many cases of biliary tract infection, urinary infection,and bacteria caused by *R.ornithinolytica* have been reported⁽²⁹⁾ . “Infections by *R. ornithinolytica* are exceedingly rare in humans and have been reported as bloodstream, urinary tract and soft tissue infections in adults and as fatal neonatal infections. Most adult cases are linked with underlying diseases, especially malignancies”⁽²³⁾.

Relation between *R.ornithinolytica* and gender

The prevalence of *R.ornithinolytica* was analyzed according to persons gender among the10 case is positive, almost all infections were detected in female which were 9 case (0.38%),and 1 case is positive in men, in our study the higher rate of *R.ornithinolytica* was found in females compere to male, this is may be due to that we collected the sample more from female than in male . On the other hand Alonso *et al*⁽³⁰⁾ recorded that 79 cases of female and male infected by *R.ornithinolytica* mean age was 62.2 years , the percentage of infection greater for male patients (63.3%) than female while results reported by Ahmed and Ali (31) showed the presence of *R.ornithinolytica* 1.4% isolated only from women with vaginitis.

Antibiotic susceptibility testing for *R. ornithinolytica*

Cefepime & imipenem, Ertapenem, Ceftazidium, and levofloxacin exhibited the highest levels of sensitivity(90%) in *R. ornithinolytica* isolates, indicating that these antibiotics remain active against this bacteria and can be used as a therapeutic treatment. Cefazolin and Trimethoprim/Sulfamethoxazol *exhibited the highest levels of resistance(70%) in these isolates..* In our investigation, the percentages of isolates resistant to ceftriaxone, Gentamycin, and Ciprofloxacin(4%,6%, and1%, respectively) were greater than those reported by (Zhou)(32). Six incidences of ampicillin resistance have been reported(34). *R. ornithinolytica* environmental isolates are susceptible to amino-and carboxypenicillin when combined with clavulanic acid. There has been some reported resistance to antibiotics such ciprofloxacin and cotrimoxazole(33) Given that the patient received 2 weeks of SXT therapy prior to the isolation of Ro25687, it is important to note that all isolates were susceptible to trimethoprim-sulfamethoxazole (SXT) except for *R. ornithinolytica* strain Ro25687. This suggests that the patient was not infected by the same strain or that the use of antibiotics contributed to SXT resistance under the selective pressure of SXT usage.. Only North America has seen reports of carbapenemase-resistant *R. ornithinolytica* strains thus far (34). In the future, screening of *R. ornithinolytica* clinical isolates for reduced susceptibility to antibiotics will improve our understanding of the mechanisms underlying increased antibiotic resistance while Al-Hulu(36). from Hila /Iraq reported that now-a-days, *R. ornithinolytica* acquired resistance against broad range of antimicrobials, most of the clinical isolates of *R. ornithinolytica* were found resistant to all class of antimicrobials such as While Al-Hulu(36) from Hila, Iraq, claimed that *R. ornithinolytica* has recently developed resistance to a wide variety of antibiotics, the majority of clinical isolates of this organism were shown to be resistant to all classes of antibiotics, including ampicillin, amoxicillin, cephalothin,

cephotaxime, chloramphenicol, penicillin, gentamicin, rifampin, and streptomycin but Nitrofurantoin and meropenam showed highest sensitivity for *R. ornithinolytica* in all the clinical samples in hilla city/ Iraq and study in Erbil recorded by(Ahmed and Ali(number)⁽³¹⁾ showed that *R. ornithinolytica* was (100%) resistant to Amikacin, Aztreonam, Clindamycin and Cefoxitin.*Raoultella spp* are often susceptible to most beta-lactam agents, however isolates that produce extended-spectrum beta lactamases and carbapenemases have emerged and MDR emergence of *R. ornithinolytica* is a global health problem commonly associated with bacteremia, urinary tract infection, neonatal infections, and exist in underlying existing infection⁽²⁷⁾.*Raoultella spp* are often susceptible to most beta-lactam agents, however isolates that produce extended-spectrum beta lactamases and carbapenemases have emerged . Although typical beta-lactam medications may often kill *Raoultella spp.*, some isolates have arisen that manufacture extended-spectrum beta lactamases and carbapenemases (37MDR's growth as a global health issue is frequently linked to bacteremia, UTI, newborn infections, and the presence of underlying illnesses. Growing bacterial resistance to antimicrobials poses a serious threat to human health as well as an economic issue, ultimately resulting in the survival of the resistant germs and the eradication of the susceptible ones. Alterations to cell membranes are major mechanistic routes linked to resistance in microorganisms, and these changes result in reduced drug uptake (38) . This bacterium, along with other dangerous bacteria, became resistant to several antibiotic groups due to antibiotic abuse, which takes the form of using antibiotics without a prescription or in an inappropriate manner.. Increased bacterial susceptibility to antimicrobials poses a serious threat to human health and an issue for the economy, allowing resistant bacteria to survive and killing susceptible ones. The results of the current study showed that *R. ornithinolytica* isolates had a high level of resistance, indicating the need for local or national studies to characterize and monitor multiresistance antibiotics and to design tactics that would hasten management and control Also, hospitalized patients and staff could significantly lower the frequency and spread of such instances by using antibiotic combination therapy against multiresistant bacteria and practicing good hygiene. The ecology and physiology of the bacteria can influence antibiotic resistance patterns, and these differences may point to different modes and processes of resistance acquisition.

Antibiotic resistance patterns and ESBL Producing for *R.ornithinolytica* isolates

The indiscriminate use of antimicrobials over prolonged periods has led to emergency of MDR strain. Whenever new and effective antibiotic is introduced bacteria after exposure to this antimicrobial, acquire resistance through different mechanism, commonest being the production of β -lactamase. Production of ESBLs by this organisms have made even the third generation cephalosporins ineffective. To combat this MDR strains new and more effective antibiotics are required⁽³⁷⁾ In interested finding in this part of the study was a association of *R.ornithinolytica* with β -lactamase. Therefore in present study vitek 2 system were used for detection β -lactamase production among *R.ornithinolytica* and showed that 6(60%)isolates of *R.ornithinolytica* ESBL producer, in general all isolated *R.ornithinolytica* were resistance to more than 8 antibiotics and one isolates completely resistance to all thirteen antibiotics(multi drug resistance The

prevalence of ESBLs among clinical isolates differ in different countries and in different hospital and are rapidly changing over time ⁽³⁷⁾. “A surface water isolate of *Raoultella* spp. having ability to multidrug and multimetal resistance ,these drugs like ampicillin , amoxicillin / clavulanic acid” ⁽³⁹⁾ . “*Raoultella*spp.have a penicillinase that related β –lactam resistance pattern. Penicillinase of *Raoultella* spp. That related β –lactam resistance suggesting the presence of a chromosomal β –lactam gene” ⁽⁴⁰⁾ . “In 2009 Al Hulu *et al.* founded that all isolates of *Raoultella ornithinolytica* were resist to ampicillin , cephalothin and other groups of beta lactam antibiotics .Some isolates of *Raoultella ornithinolytica* have resistant to ampicillin and other antibiotics ,this resistance can be associated with the presence of β –lactamases”⁽⁴¹⁾. “Many clinical microbiological laboratories still face significant problems ESBL screening and identification as ESBL pathogenesis can present with variations in the vitro pattern of resistance of β -lactamase agent. Proficiency testing study performed by the World Health Organization and Centers for Disease Control have raised concerns about the current ability of many clinical laboratories to detect ESBL-Producing microorganism” ⁽⁴²⁾ .

References

- 1-Drancourt M, Bollet C, Carta A, Rousselier.** phylogenetic analyses of *Klebsiella* species delineate *Klebsiella* and *Raoultella* gen. nov; with description of *Raoultella ornithinolytica* comb. nov ,*Raoultella terrigena* com. nov. and *Raoultella planticola* com.nov. International Journal of Systematic and Evolutionary Microbiology .2001.51(pt3):925-32.
- 2.Park J S, Hong K H ,Lee H J, Choi S H, Song J H, Song K H, Kim H B, Park K U, Song J, and Kim E.** Evaluation of three phenotypic identification systems for clinical isolate of *Raoultella ornithinolytica* ,J. Med. Microbiol. 2011.60:492-499.
- 3-Jain K , Radsak K , W Mannheim.** Differentiation of the Oxytocum group from *Klebsiella* by deoxyribonucleic acid hybridization.Int J Syst Bacteriol.1974 . 4 (4): 402-407.
- 4- Kanki M, Yoda T, Tsukamoto T, Shibata T.***Klebsiella pneumoniae* produces no histamine: *Raoultella planticola* and *Raoultella ornithinolytica* strains are histamine producers. Appl Environ Microbiol.2002.;68:3462–6
- 5- Sakazaki R, Tamura K , Kosako Y,and Yoshizaki E.** *Klebsiella ornithinolytica* spp Nov, formerly known as ornithino-positive *Klebsiella oxytoca*.Curr. Microbiol. . 1989 .18: 201-206.
- 6- Bagley S T, Seidler R J, Albot H W J,and Morrow J E.** Isolation of *Klebsiella* from living wood. Appl. Environ. Microbiol. 1978 . 36: 178-185.

- 7- Monnet D J, Freney Y, Brun J M, Boeufgras, and Fleurette J.** Difficulties in identifying *Klebsiella* strains of clinical origin. Zentralbl .Bakteriol. Parasitenkd. Infektionskr. Hyg.Abt. 1 Orig.1991 .274:456–464
- 8.Heggendorn F L, Gonçalves L S, Dias E P ,Silva A, Junior M Galvão M, Lutterbach M.** Detection of sulphate-reducing bacteria in human saliva ActaOdontol Scand.2013 . pp. 71,1458-1463,
- 9.Morais V P, Daporta M T, Bao A F, Campello M G, Andrés G Q.** Enteric fever-like syndrome caused by *Raoultella ornithinolytica* (*Klebsiella ornithinolytica*) J Clin Microbiol. 2009.47:868–9
- 10.Murray P R, Baron E J, Jorgensen H J, Landry M L, and Pfaller M A.** Manual of clinical microbiology, 9th edition, vol. 1. ASM Press, Washington, DC. 2007.
- 11-. Alves M S , Riley L W, and Moreira B M.** A case of severe pancreatitis complicated by *Raoultella planticola* infection. J. Med. Microbiol.2007. 56:696-698.
- 12-Deeb L S, Bajaj J, Bhargava S, Alcid D, pitchumoni C S.** Acute suppuration of the pancreatic duct in a patient with tropical pancreatitis. Case Rep Gastroenterol.2008.2(1):2732.
- 13- Podschun R, Sievers D, Fischer A, Ullmann U.** Serotypes, hemma-gglutinins, siderophore synthesis, and serum resistance of *Klebsiella* isolates causing human urinary tract infections. J Infect Dis.1993 . 168: 1415-1421.
- 14.Walckenaer E, Poire L I, Leflon-Guibout V, Nordmann P, Nicolas-Chanoine M H.** Genetic and biochemical characterization of the chromosomal class A β -lactamases of *Raoultella* (formerly *Klebsiella*) *planticola* and *Raoultella ornithinolytica*. Antimicrob Agents Chemother.2004 .pp.48. 305-312,
- 15-Hostacká A, Klokocníková L.** Antibiotic susceptibility, serum response and surface properties of *Klebsiella* species Microbios.2001.pp.104. 115-124
- 16-Eigner U, Schmid A, Wild U, Bertsch D and Fahr A M.** Analysis of the comparative workflow and performance characteristics of the VITEK 2 and Phoenix systems. Journal of Clinical Microbiology. 2005; 43: 3829-3834.

- 17. Zhou G, Guo S, Luo Y, Ye L, Song Y, Sun G, et al.** NDM-1-producing strains, family *Enterobacteriaceae*, in hospital, Beijing, China Emerg Infect Dis. 2014 .pp.20. 340-342,
- 18. Richter S S, Sercia L, Branda J A, Burnham C A, Bythrow M, Ferraro M J, et al** .Identification of *Enterobacteriaceae* by matrix-assisted laser desorption/ionization time-of flight mass spectrometry using the VITEK MS system .Eur J Clin Microbiol Infect Dis. 2013 . pp.32.1571-1578,
- 19- Hansen D S, Aucken H M, Abiola T, Podschun R** .Recommended test panel for differentiation of *Klebsiella* species on the basis of a trilateral interlaboratory evaluation of 18 biochemical tests. J Clin Microbiol.2004. 42: 3665-3669
- 20-Al-Charrackh A H.** Isolation of *Raoultellaplanticola* from clinical specimens in Hillacity. Proceedings of 3rd Conference of Microbiology and Biotechnology,Basrah, Iraq. 2007.
- 21-Kuhn I ,Ayling-Smith B, Tullus K , and Burman G.**The use of colonization rate and epidemic index as tools to illustrate the epidemiology of faecal *Enterobacteriaceae* strains in Swedish neonatal wards. J. Hosp. Infect. 1993.23: 287-297.
- 22- Vos B, Laureys M.** Giant renal cyst as cause of colic obstruction. Rev Med Brux. 2009.30:107-9.
- 23-Mau N, Ross L A.** *Raoultella ornithinolytica* bacteremia in an infant with visceral heterotaxy. Pediatr Infect Dis J. 2010.29:1-2.
- 24. Alves M S , Riley L W, and Moreira B M.** A case of severe pancreatitis complicated by *Raoultella planticola* infection. J. Med. Microbiol.2007. 56:696-698.
- 25.Sproßer C ,Mendrock U, Swiderski J, Lang E & Stackebrandt E.**The phylogenetic position of *Serratia*, *Buttiauxella* and some other genera of the family *Enterobacteriaceae*.Int J Syst Bacteriol.1999 .49, 1433±1438.

- 26. Kwon S W, Go S J, Kang H W, Ryu J C, & Jo J K.** Phylogenetic analysis of *Erwinia* species based on 16S Rrna gene sequence. *Int J Syst Bacteriol.* 1997 .47, 1061±1067.
- 27- Tenover F C .** Mechanisms of antimicrobial resistance in bacteria. *Am J Infect Control.* 2006. 119: S3-S10
- 28- Seleden R, Lee S, Wang W L, Bannett J V, and Eickhoff T C.** Nosocomial *Klebsiella* infections: intestinal colonization as a reservoir. *Ann. Intern. Med.* 1971. 74: 657- 664.
- 29. Chun S, Yun J W, Huh H J, Lee Clinical N Y.** Characteristics of *Raoultella ornithinolytica* bacteremia *Infection.* 2015. pp 43 . 59-64,
- 30- Alonso M P, Rojas1 L R, Campo1 R D , Cantón R and Morosini .** Comparison of different methods for identification of species of the genus *Raoultella*: report of 11 cases of *Raoultella* causing bacteraemia and literature review .*Clin Microbiol Infect .* 2016. 22: 252–257
- 31- Ahmad S S, and Ali F A.** Detection of ESBL, Ampc and metallo Beta- lactamase mediated resistance in gram- negative bacteria isolated from women with genital tract infection1 .*European Scientific Journal .* 2014 edition vol.10, no.9
- 12. Zhou G, Guo S, Luo Y, Ye L, Song Y, Sun G, et al.** NDM-1-producing strains, family *Enterobacteriaceae*, in hospital, Beijing, China *Emerg Infect Dis.* 2014 .pp.20. 340-342,
- 33. García-Lozano T, Pascual Plá F J, Aznar O.** [*Raoultella ornithinolytica* in urinary tract infections. Clinical and microbiological study of a series of 4 oncologic patients] .*Med Clínica.* 2013 .141, pp. 138-139,
- 34. Brooks G F, Butel J S, and Morse S A.** Jawetz, Melnick and Adelberg's. *Medical Microbiology.* Twenty-Third ed. McGraw Hill Education (Asia). Singapore. 2004 .
- 35. Tije tN, Sheth P M, Lastovetska O, Chung C, Patel S N ,Melano R G.** 2014. Molecular characterization of *Klebsiella pneumoniae* carbapenemase (KPC) producing

Enterobacteriaceae in Ontario, Canada. 2008-2011. PLoS One 9: e116421. 10.1371/ Journal Pone. 0116421.

36- Al-Hulu S M, Al-Charrakh A H, Al-Saadi M A K. Isolation and characterization of *Raoultella ornithinolytica* from clinical specimens in Hilla city. Iraq Med J Babylon.2009. 7: 42-47.

37-Mumtaz S, Ahmad M, Aftab I, Akhtar N and Hameed A. In vitro comparative efficacy of Carbapenims β -lactamase β -lactamase inhibitor combinations against multidrug resistant gram negative bacilli. Gomal Journal of Medical Science.2018.;6(1): 1-6 .

38-Sambrook J, and Rusell D W. Molecular cloning. A laboratory manual.3rt cold .Spring.Harber Laboratory Press, N. Y.2001 .

39- Koc S, Kabatas B, and Icgen B. Multidrug and heavy metal –resistant *Raoultella planticola* isolated from surface water . Bull Environ Contam Toxicol.US National library of Medicine National Institutes of health . 2013 .91(2):177-83.

40.Walckenaer E, Poire L I, Leflon-Guibout V, Nordmann P, Nicolas-Chanoine M H. Genetic and biochemical characterization of the chromosomal class A β -lactamases of *Raoultella* (formerly *Klebsiella*) *planticola* and *Raoultella ornithinolytica* .Antimicrob Agents Chemother.2004 .pp.48. 305-312,

41-Hostacká A, Klokocníková L. Antibiotic susceptibility, serum response and surface properties of *Klebsiella* species .Microbios.2001.pp.104. 115-124

42-Hageman J C, Fridkin S K, Mohammed J M, Steward C D, Gaynes R P and Tenover F C. Antimicrobial proficiency testing of national nosocomial infections surveillance system Hospital Laboratories. Infection Control Hospital Epidemiology Journal .2003.24:356-361.